|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigates the occurrence of the BRAF V600E mutation in these tumors.A cohort of 64 PHEO/PARA were screened for the BRAF V600E mutation using direct Sanger sequencing and QRT-PCR.All cases investigated displayed wild-type without V600E BRAF mutationTaken together with all previously screened tumors up to date, only 1 V600E BRAF mutation has been found among 427 PCCs.
|
28043156 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Application of the IHC VE1 assay was highly feasible in primary/metastatic sites or effusion blocks, yielding positive findings in 28 of 29 (96.6%) <i>BRAF</i> V600E-mutated tumors and negative results in 69 of 70 (98.6%) tumors harboring other types or undetected mutations.
|
31234388 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we tested the BETi, PLX51107, for immune-based effects on tumor growth in BRAF V600E melanoma syngeneic models.
|
31063649 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
|
31672130 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, we identified a subset of BRAF(V600E) tumors that were resistant to the combined treatment, in which FGFR was found to drive feedback-induced RAS activation, independently of SHP2.
|
30605687 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of BRAF-V600E mutations in ameloblastoma was related to decreased levels of glycerol in comparison with tumors carrying only wild-type alleles of this gene.
|
30739334 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The association between clinical-pathologic features and BRAF V600E mutation in ameloblastomas may provide directions for the treatment of this neoplasia.
|
29855709 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, SATB2-negative and/or CDX2-negative expression was identified in 33% of mismatch repair protein deficient tumors compared with only 15% of mismatch repair protein proficient tumors (p < 0.001) and in 36% of BRAF V600E mutated compared with only 13% of BRAF wild-type tumors (p < 0.001).
|
30962505 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity.
|
31434983 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the case of BRAF-V600E mutant melanoma, ERK inhibition has emerged as a viable clinical approach to abrogate signaling through the ERK pathway, even in cases where MEK and Raf inhibitor treatments fail to induce tumor regression due to resistance mechanisms.
|
31190430 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Future studies with long-term follow-up are required to determine if pediatric BRAF V600E positive CNS-JXG neoplasms are a distinct entity in the L-group histiocytosis category or represent an expanded pediatric spectrum of ECD.
|
31685033 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
It was demonstrated that in these tumors BRAF V600E mutated and that CDKN2A/B MTAP co-deletions may be used for stratifying patients for a stricter surveillance.
|
30558563 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In a series of 38 patients who met clinical criteria for Lynch syndrome genetic testing, with loss of MLH1 expression in the tumor and with no germline mutations in the MLH1 gene (35/38) or with tumors presenting the BRAF p.Val600Glu mutation (3/38), we screened for constitutional methylation of the MLH1 gene promoter using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) in various biological samples.
|
29341452 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor DNA was tested for microsatellite instability (MSI) and somatic mutations in oncogenes BRAF (V600E) and KRAS.
|
28921583 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The expression of LIMD2 in primary tumors was correlated with the presence of BRAF V600E mutation (P = 0.0338).
|
29560564 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-V600E mutant-type showed better OS than V600E mutant-type (P = 0.038), with no significant difference compared with wild-type tumors.
|
30463788 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Small-molecule inhibitors of β-catenin or FAK synergize with vemurafenib BRAF inhibitor to prevent <i>BRAF</i> V600E colorectal cancer cell proliferation <i>in vitro</i> and xenograft tumor growth in mice.
|
29610281 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This tumor had histologic and immunophenotypic features similar to the recently described PLNTY and proved BRAF V600E mutant.
|
29701169 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among CD34+ cases, we proposed a new entity of BRAF V600E positive HS and we described three hippocampal multinodular and vacuolating neuronal tumors.
|
29476662 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report that chondroitin-4-sulfate (CHSA), a natural glycosaminoglycan approved as a dietary supplement used for osteoarthritis, selectively promotes the tumor growth potential of BRAF V600E-expressing human melanoma cells in patient- and cell line-derived xenograft mice and confers resistance to BRAF inhibitors.
|
29547721 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We demonstrate in this first series of midline GGs that the H3 K27M mutation can occur in association with the BRAF V600E mutation in grade I glioneuronal tumors.
|
27984673 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
No BRAF V600E was found in all follicular-patterned tumors.
|
29723601 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prior BRAF V600E mutation testing was examined for these tumors when available.
|
29368294 |
2018 |